Ozempic face is real, but the horror framing is overblown

What did @patricia_venco actually say?

The transcript here is largely incoherent, likely the result of poor auto-transcription from German audio. Based on the caption, the creator is warning viewers about "Ozempic Face", describing it as the visible physical toll of using semaglutide for weight loss rather than its approved use in type 2 diabetes. The caption frames it as a "horror" outcome: fat loss that leaves the face looking gaunt, aged, or hollow. The phrase "der Preis ist hoch" (the price is high) frames aesthetic side effects as a serious cost of off-label use.

The underlying argument, pieced together from the caption, is that celebrities and healthy people are using Ozempic purely for cosmetic weight loss, and that "Ozempic Face" is the consequence. That is a legitimate topic worth examining. But the execution matters, and a 737,000-view video built on fear framing deserves a closer look at whether the fear is earned.

Does the science back this up?

Partially, yes. Facial fat loss during rapid weight reduction is real and well-documented, but it is not specific to semaglutide. This is where the creator oversimplifies.

A 2023 commentary in JAMA Dermatology (Hartman et al.) acknowledged that clinicians were seeing patients with increased facial aging appearance following GLP-1-driven weight loss, but the authors were careful to note the mechanism is weight loss itself, not the drug. Fat compartments in the face, particularly the buccal and temporal fat pads, shrink with significant caloric deficit regardless of how that deficit is achieved. Ozempic accelerates weight loss, so it accelerates facial volume loss, but so does bariatric surgery, aggressive caloric restriction, or any other method producing 10-15% body weight reduction.

The term "Ozempic Face" was popularized in late 2022 by New York dermatologist Dr. Paul Jarrod Frank in media interviews, not in peer-reviewed literature. It is a catchy label, not a clinical diagnosis. No published trial has shown semaglutide directly causes facial fat loss independent of the weight loss it produces.

What did they get wrong (or right)?

They got the core concern directionally right: rapid, significant weight loss can age the face, and semaglutide produces rapid, significant weight loss. Credit for that.

What they got wrong is the framing. Calling it "Ozempic Face" implies the drug itself is doing something uniquely damaging to facial tissue. It is not. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants lost an average of 14.9% of body weight over 68 weeks. Losing that much weight from any cause will change how your face looks. A person who lost the same weight through diet and exercise could experience the same outcome.

The "healthy people using it just to lose weight" framing is also slippery. Wegovy, not Ozempic, is FDA-approved for chronic weight management in people with a BMI of 30 or higher, which is a clinical threshold, not a vanity metric. Framing all non-diabetic users as Hollywood vanity cases misrepresents how these medications are actually prescribed.

What should you actually know?

If you lose a significant percentage of your body weight, your face will likely change. This is not a semaglutide-specific risk. It is a weight-loss biology fact. The rate of loss matters too: slower weight loss gives skin and soft tissue more time to adapt.

Dermatologists do have tools to address volume loss, including hyaluronic acid fillers and biostimulators, but these are cosmetic interventions and come with their own considerations. No injectable filler is a substitute for discussing realistic expectations with a prescribing clinician before starting any weight-loss medication.

The bigger issue with videos like this one is that they use legitimate science, facial fat loss is real, to manufacture fear about a medication class that has also shown meaningful cardiovascular benefits. The SELECT trial (Lincoff et al., 2023, New England Journal of Medicine) found semaglutide reduced major cardiovascular events by 20% in people with obesity and established cardiovascular disease. That context is absent from a video titled "Horror."

Weight loss drugs have real side effects worth discussing. Nausea, gastrointestinal symptoms, and the potential for muscle mass loss alongside fat loss are all documented. The face changing after significant weight loss is real. But "horror" framing without clinical nuance leaves viewers more anxious and less informed, which helps no one.